RESUMO
Thrombosis promotes leukocyte infiltration into inflamed tissues, leading to organ injury in a broad range of diseases; however, the mechanisms by which thrombi guide leukocytes to sites of vascular injury remain ill-defined. Using mouse models of endothelial injury (traumatic or ischemia reperfusion), we demonstrate a distinct process of leukocyte recruitment, termed "directed intravascular migration," specifically mediated by platelet thrombi. Single adherent platelets and platelet aggregates stimulated leukocyte shape change at sites of endothelial injury; however, only thrombi were capable of inducing directed intravascular leukocyte migration. Leukocyte recruitment and migration induced by platelet thrombi occurred most prominently in veins but could also occur in arteries following ischemia-reperfusion injury. In vitro studies demonstrated a major role for platelet-derived NAP-2 (CXCL-7) and its CXCR1/2 receptor in regulating leukocyte polarization and motility. In vivo studies demonstrated the presence of an NAP-2 chemotactic gradient within the thrombus body. Pharmacologic blockade of CXCR1/2 as well as genetic deletion of NAP-2 markedly reduced leukocyte shape change and intrathrombus migration. These studies define a distinct process of leukocyte migration that is initiated by homotypic adhesive interactions between platelets, leading to the development of an NAP-2 chemotactic gradient within the thrombus body that guides leukocytes to sites of vascular injury.
Assuntos
Plaquetas/citologia , Quimiocinas CXC/metabolismo , Leucócitos/citologia , Receptores de Interleucina-8A/metabolismo , Receptores de Interleucina-8B/metabolismo , Trombose/imunologia , Animais , Plaquetas/imunologia , Plaquetas/metabolismo , Adesão Celular/imunologia , Movimento Celular/imunologia , Polaridade Celular/imunologia , Proteínas de Fluorescência Verde/genética , Leucócitos/imunologia , Artérias Mesentéricas/imunologia , Artérias Mesentéricas/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Ferimentos Penetrantes Produzidos por Agulha/imunologia , Ferimentos Penetrantes Produzidos por Agulha/patologia , Neutrófilos/citologia , Neutrófilos/imunologia , Traumatismo por Reperfusão/imunologia , Traumatismo por Reperfusão/patologiaAssuntos
Inibidores dos Fatores de Coagulação Sanguínea/antagonistas & inibidores , Bortezomib/uso terapêutico , Fator VIII/antagonistas & inibidores , Fator VIII/imunologia , Hemofilia A/tratamento farmacológico , Hemofilia A/etiologia , Isoanticorpos/imunologia , Hematoma/diagnóstico por imagem , Hematoma/etiologia , Hemofilia A/sangue , Hemofilia A/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores de Proteassoma/uso terapêutico , Tomografia Computadorizada por Raios X , Resultado do TratamentoAssuntos
Compostos de Anilina/uso terapêutico , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Transtornos Linfoproliferativos/tratamento farmacológico , Transtornos Linfoproliferativos/metabolismo , Glicoproteínas de Membrana/metabolismo , Sulfonamidas/uso terapêutico , Humanos , Complexo Glicoproteico GPIb-IX de Plaquetas , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidoresAssuntos
Transplante de Coração , Infecções por Parvoviridae/diagnóstico , Aplasia Pura de Série Vermelha/diagnóstico , Adulto , Feminino , Humanos , Terapia de Imunossupressão , Infecções por Parvoviridae/complicações , Infecções por Parvoviridae/imunologia , Infecções por Parvoviridae/virologia , Parvovirus B19 Humano/fisiologia , Reação em Cadeia da Polimerase , Aplasia Pura de Série Vermelha/complicações , Aplasia Pura de Série Vermelha/imunologia , Aplasia Pura de Série Vermelha/virologiaRESUMO
Certain patients with antibody-mediated autoimmune disease exhibit poor responses to conventional immunosuppression, including B-cell depletion with rituximab. Proteasome inhibitors such as bortezomib demonstrate pleiotropic immunomodulatory effects, including direct toxicity to antibody-producing cells. Here, we report preliminary evidence for the efficacy of bortezomib as salvage therapy for refractory autoimmune hematological disease. Thirteen treatment episodes in 10 patients with autoimmune hematological phenomena (autoimmune hemolytic anemia [AIHA; n = 8], acquired hemophilia (n = 1), immune thrombocytopenia (n = 1), and thrombotic thrombocytopenic purpura [TTP; n = 3]) and a median of 5 (range, 3-12) prior lines of therapy demonstrated an overall response rate of 77% (10 of 13) including 38% (5 of 13) complete remissions. The majority of clinical improvements were rapid, correlated with biomarkers of autoantibody reduction, and were associated with an acceptable safety profile. Responses appeared durable following treatment of TTP and acquired hemophilia; AIHA responses were more limited with a pattern of relapse following bortezomib cessation. These data provide proof of concept for the utility of proteasome inhibition as antibody depletion therapy in autoimmune disease.
RESUMO
Although the role of platelets as central mediators of hemostasis and thrombosis has been the primary focus of research into platelet biology for more than a century, over the last decade, nonhemostatic functions of platelets have been increasingly defined. As such, a large body of experimental evidence now exists, which places the platelet as a key player in mediating a diverse range of immune, inflammatory, and malignant disease processes. This review outlines the central mechanisms that underpin the nonhemostatic role of platelets and provides a summary of evidence demonstrating a role for platelets in mediating selected inflammatory, immune, and malignant disease processes.
Assuntos
Plaquetas/fisiologia , Sistema Imunitário/fisiologia , Inflamação/fisiopatologia , Neoplasias/fisiopatologia , Animais , Infecções Bacterianas/imunologia , Plaquetas/imunologia , Antígenos CD40/fisiologia , Endotélio Vascular/patologia , Hemostasia/fisiologia , Humanos , Leucócitos/fisiologia , Camundongos , Receptores Fc/imunologia , Receptores Toll-Like/imunologia , Reação Transfusional/fisiopatologiaRESUMO
Thrombin is a central regulator of leukocyte recruitment and inflammation at sites of vascular injury, a function thought to involve primarily endothelial PAR cleavage. Here we demonstrate the existence of a distinct leukocyte-trafficking mechanism regulated by components of the haemostatic system, including platelet PAR4, GPIbα and fibrin. Utilizing a mouse endothelial injury model we show that thrombin cleavage of platelet PAR4 promotes leukocyte recruitment to sites of vascular injury. This process is negatively regulated by GPIbα, as seen in mice with abrogated thrombin-platelet GPIbα binding (hGPIbα(D277N)). In addition, we demonstrate that fibrin limits leukocyte trafficking by forming a physical barrier to intravascular leukocyte migration. These studies demonstrate a distinct 'checkpoint' mechanism of leukocyte trafficking involving balanced thrombin interactions with PAR4, GPIbα and fibrin. Dysregulation of this checkpoint mechanism is likely to contribute to the development of thromboinflammatory disorders.
Assuntos
Leucócitos/fisiologia , Ativação Plaquetária , Complexo Glicoproteico GPIb-IX de Plaquetas/metabolismo , Receptores de Trombina/metabolismo , Trombina/metabolismo , Animais , Movimento Celular , Células Endoteliais/fisiologia , Fibrinólise , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Modelos AnimaisRESUMO
Platelets have evolved highly specialized adhesion mechanisms that enable cell-matrix and cell-cell interactions throughout the entire vasculature irrespective of the prevailing hemodynamic conditions. This unique property of platelets is critical for their ability to arrest bleeding and promote vessel repair. Platelet adhesion under conditions of high shear stress, as occurs in stenotic atherosclerotic arteries, is central to the development of arterial thrombosis; therefore, precise control of platelet adhesion must occur to maintain blood fluidity and to prevent thrombotic or hemorrhagic complications. Whereas the central role of platelets in hemostasis and thrombosis has long been recognized and well defined, there is now a major body of evidence supporting an important proinflammatory function for platelets that is linked to host defense and a variety of autoimmune and inflammatory diseases. In the context of the vasculature, experimental evidence indicates that the proinflammatory function of platelets can regulate various aspects of the atherosclerotic process, including its initiation and propagation. The mechanisms underlying the proatherogenic function of platelets are increasingly well defined and involve specific adhesive interactions between platelets and endothelial cells at atherosclerotic-prone sites, leading to the enhanced recruitment and activation of leukocytes. Through the release of chemokines, proinflammatory molecules, and other biological response modulators, the interaction among platelets, endothelial cells, and leukocytes establishes a localized inflammatory response that accelerates atherosclerosis. These inflammatory processes typically occur in regions of the vasculature experiencing low shear and perturbed blood flow, a permissive environment for leukocyte-platelet and leukocyte-endothelial interactions. Therefore, the concept has emerged that platelets are a central element of the atherothrombotic process and that future therapeutic strategies to combat this disease need to take into consideration both the prothrombotic and proinflammatory function of platelets.